Medication-related osteonecrosis of the jaw in patients with bone metastases from solid tumors: analysis of the Istituto Oncologico Veneto case series

Treatment of BM bone metastases from solid tumors often includes the use of bone antiresorptive agents (BAA) beside tumor-directed specific treatment.  Medication-related osteonecrosis of the jaw (MRONJ) is a severe side effect caused by BAA. This retrospective study evaluates the incidence of MRONJ in a real-world setting of patients with solid tumors treated with BAA for BM at Istituto Oncologico Veneto (IOV). Data for patients with solid tumors who received BAA for BM between January 2010 and December 2017 at Istituto Oncologico Veneto, Padua, Italy were retrieved from a prospectively maintained database, 1211 patients met the inclusion criteria and received BAA . In addition , we  defines the time to onset (TTO) and assess the role of dental prevention.